Table 2.

Studies of inhaled tobramycin in CF patients with P. aeruginosa present in sputum.

Study/Year	Preparation	Dose/Frequency	Duration	Patient Population	Key Outcomes after Treatment
MacLusky 1989 [30]	TSI	80 mg/TID	32 months	n = 27	Stability in pulmonary function, controls showed decline
Smith 1989 [33]	TSI	600 mg/TID	12 weeks	n = 22	Improved symptoms, decrease in bacterial density
Ramsey 1993 [29]	TSI	600 mg/TID	12 weeks, 28 days on, 28 days off	n = 71	Improved pulmonary function
Ramsey 1999 [26]	TSI	300 mg/BID	24 weeks (on/off every 28 days)	n = 520	Improved pulmonary function and decreased hospitalizations
Gibson 2003 [31]	TSI	300 mg/BID	28 days	n = 21	Treatment reduced lower airway P. aeruginosa density
Murphy 2004 [32]	TSI	300 mg/BID	28 days on, 28 days off (7 cycles)	n = 184, mild lung disease	Decreased hospitalization rates
Konstan 2011 [44]	TIP or TSI	112 mg/BID or 300 mg/BID	28 days on, 28 days off (3 cycles)	n = 517	Comparable efficacy, but greater satisfaction with inhalation powder
Galeva 2013 [46]	TIP	112 mg/BID	28 days on, 28 days off (1 cycle)	n = 62	Trend towards improvement in the lung function

BID, twice daily; TID, three times daily; TSI, tobramycin solution for inhalation; TIP, tobramycin inhalation powder.